FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978960033> ?p ?o ?g. }

• W1978960033 endingPage "1243" @default.
• W1978960033 startingPage "1235" @default.
• W1978960033 abstract "The Biopharmaceutical Classification System (BCS) guidance issued by the FDA allows waivers for in vivo bioavailability and bioequivalence studies for immediate-release (IR) solid oral dosage forms only for BCS class I drugs. However, a number of drugs within BCS class III have been proposed to be eligible for biowaivers. The World Health Organization (WHO) has shortened the requisite dissolution time of BCS class III drugs on their Essential Medicine List (EML) from 30 to 15 min for extended biowaivers; however, the impact of the shorter dissolution time on AUC(0-inf) and C(max) is unknown. The objectives of this investigation were to assess the ability of gastrointestinal simulation software to predict the oral absorption of the BCS class I drugs propranolol and metoprolol and the BCS class III drugs cimetidine, atenolol, and amoxicillin, and to perform in silico bioequivalence studies to assess the feasibility of extending biowaivers to BCS class III drugs. The drug absorption from the gastrointestinal tract was predicted using physicochemical and pharmacokinetic properties of test drugs provided by GastroPlus (version 6.0). Virtual trials with a 200 mL dose volume at different drug release rates (T(85%) = 15 to 180 min) were performed to predict the oral absorption (C(max) and AUC(0-inf)) of the above drugs. Both BCS class I drugs satisfied bioequivalence with regard to the release rates up to 120 min. The results with BCS class III drugs demonstrated bioequivalence using the prolonged release rate, T(85%) = 45 or 60 min, indicating that the dissolution standard for bioequivalence is dependent on the intestinal membrane permeability and permeability profile throughout the gastrointestinal tract. The results of GastroPlus simulations indicate that the dissolution rate of BCS class III drugs could be prolonged to the point where dissolution, rather than permeability, would control the overall absorption. For BCS class III drugs with intestinal absorption patterns similar to those of cimetidine, atenolol or amoxicillin, the dissolution criteria for extension of biowaivers to BCS class III drugs warrants further investigation." @default.
• W1978960033 created "2016-06-24" @default.
• W1978960033 creator A5036898947 @default.
• W1978960033 creator A5085453188 @default.
• W1978960033 date "2010-06-28" @default.
• W1978960033 modified "2023-10-01" @default.
• W1978960033 title "The Biowaiver Extension for BCS Class III Drugs: The Effect of Dissolution Rate on the Bioequivalence of BCS Class III Immediate-Release Drugs Predicted by Computer Simulation" @default.
• W1978960033 cites W1498305210 @default.
• W1978960033 cites W1498992899 @default.
• W1978960033 cites W1596837460 @default.
• W1978960033 cites W1596962878 @default.
• W1978960033 cites W1686717621 @default.
• W1978960033 cites W1779958190 @default.
• W1978960033 cites W1971181330 @default.
• W1978960033 cites W1976855253 @default.
• W1978960033 cites W1979184433 @default.
• W1978960033 cites W1983346346 @default.
• W1978960033 cites W1994891003 @default.
• W1978960033 cites W1996505306 @default.
• W1978960033 cites W2004475083 @default.
• W1978960033 cites W2006661934 @default.
• W1978960033 cites W2012422694 @default.
• W1978960033 cites W2024362305 @default.
• W1978960033 cites W2044293800 @default.
• W1978960033 cites W2060854826 @default.
• W1978960033 cites W2068571157 @default.
• W1978960033 cites W2071936076 @default.
• W1978960033 cites W2088473012 @default.
• W1978960033 cites W2097275187 @default.
• W1978960033 cites W2101254927 @default.
• W1978960033 cites W2112722416 @default.
• W1978960033 cites W2113566734 @default.
• W1978960033 cites W2129827408 @default.
• W1978960033 cites W2143221948 @default.
• W1978960033 cites W2145017630 @default.
• W1978960033 cites W2161119017 @default.
• W1978960033 cites W2169939486 @default.
• W1978960033 cites W2170281823 @default.
• W1978960033 cites W2414330781 @default.
• W1978960033 cites W2616206605 @default.
• W1978960033 cites W4237999627 @default.
• W1978960033 cites W4243773020 @default.
• W1978960033 cites W4385834830 @default.
• W1978960033 cites W46982982 @default.
• W1978960033 doi "https://doi.org/10.1021/mp100053q" @default.
• W1978960033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20557130" @default.
• W1978960033 hasPublicationYear "2010" @default.
• W1978960033 type Work @default.
• W1978960033 sameAs 1978960033 @default.
• W1978960033 citedByCount "71" @default.
• W1978960033 countsByYear W19789600332012 @default.
• W1978960033 countsByYear W19789600332013 @default.
• W1978960033 countsByYear W19789600332014 @default.
• W1978960033 countsByYear W19789600332015 @default.
• W1978960033 countsByYear W19789600332016 @default.
• W1978960033 countsByYear W19789600332017 @default.
• W1978960033 countsByYear W19789600332018 @default.
• W1978960033 countsByYear W19789600332019 @default.
• W1978960033 countsByYear W19789600332020 @default.
• W1978960033 countsByYear W19789600332021 @default.
• W1978960033 countsByYear W19789600332022 @default.
• W1978960033 countsByYear W19789600332023 @default.
• W1978960033 crossrefType "journal-article" @default.
• W1978960033 hasAuthorship W1978960033A5036898947 @default.
• W1978960033 hasAuthorship W1978960033A5085453188 @default.
• W1978960033 hasConcept C112705442 @default.
• W1978960033 hasConcept C126322002 @default.
• W1978960033 hasConcept C14029885 @default.
• W1978960033 hasConcept C181389837 @default.
• W1978960033 hasConcept C22979827 @default.
• W1978960033 hasConcept C2776525901 @default.
• W1978960033 hasConcept C2780035454 @default.
• W1978960033 hasConcept C2781047461 @default.
• W1978960033 hasConcept C2781430271 @default.
• W1978960033 hasConcept C3019981671 @default.
• W1978960033 hasConcept C42404028 @default.
• W1978960033 hasConcept C54355233 @default.
• W1978960033 hasConcept C71924100 @default.
• W1978960033 hasConcept C84393581 @default.
• W1978960033 hasConcept C86803240 @default.
• W1978960033 hasConcept C98274493 @default.
• W1978960033 hasConceptScore W1978960033C112705442 @default.
• W1978960033 hasConceptScore W1978960033C126322002 @default.
• W1978960033 hasConceptScore W1978960033C14029885 @default.
• W1978960033 hasConceptScore W1978960033C181389837 @default.
• W1978960033 hasConceptScore W1978960033C22979827 @default.
• W1978960033 hasConceptScore W1978960033C2776525901 @default.
• W1978960033 hasConceptScore W1978960033C2780035454 @default.
• W1978960033 hasConceptScore W1978960033C2781047461 @default.
• W1978960033 hasConceptScore W1978960033C2781430271 @default.
• W1978960033 hasConceptScore W1978960033C3019981671 @default.
• W1978960033 hasConceptScore W1978960033C42404028 @default.
• W1978960033 hasConceptScore W1978960033C54355233 @default.
• W1978960033 hasConceptScore W1978960033C71924100 @default.
• W1978960033 hasConceptScore W1978960033C84393581 @default.
• W1978960033 hasConceptScore W1978960033C86803240 @default.
• W1978960033 hasConceptScore W1978960033C98274493 @default.
• W1978960033 hasIssue "4" @default.

• next